U.S. patent application number 13/160009 was filed with the patent office on 2011-10-13 for albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease.
This patent application is currently assigned to Dey, L.P.. Invention is credited to Partha Banerjee, Imtiaz Chaudry.
Application Number | 20110247613 13/160009 |
Document ID | / |
Family ID | 36692568 |
Filed Date | 2011-10-13 |
United States Patent
Application |
20110247613 |
Kind Code |
A1 |
Chaudry; Imtiaz ; et
al. |
October 13, 2011 |
ALBUTEROL AND IPRATROPIUM INHALATION SOLUTION, SYSTEM, KIT AND
METHOD FOR RELIEVING SYMPTOMS OF CHRONIC OBSTRUCTIVE PULMONARY
DISEASE
Abstract
The present invention relates to a dual bronchodilator
inhalation solution, system, kit and method for relieving
bronchospasm in patients suffering from chronic obstructive
pulmonary disease (COPD). In one alternative embodiment, the
solution of the present invention is a prepackaged, sterile,
premixed, premeasured single unit dose of albuterol and ipratropium
bromide for patients suffering from COPD. The present solution may
be free of antimicrobial preservatives, such as benzalkonium
chloride. In another alternative embodiment, the solution of the
present invention comprises about 2.50 mg albuterol and about 0.50
mg ipratropium bromide in a 0.5 ml volume.
Inventors: |
Chaudry; Imtiaz; (American
Canyon, CA) ; Banerjee; Partha; (Plainsboro,
NJ) |
Assignee: |
Dey, L.P.
|
Family ID: |
36692568 |
Appl. No.: |
13/160009 |
Filed: |
June 14, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11037574 |
Jan 18, 2005 |
|
|
|
13160009 |
|
|
|
|
10417723 |
Apr 15, 2003 |
|
|
|
11037574 |
|
|
|
|
PCT/US04/11705 |
Apr 15, 2004 |
|
|
|
10417723 |
|
|
|
|
10162460 |
Jun 3, 2002 |
6632842 |
|
|
PCT/US04/11705 |
|
|
|
|
10034657 |
Dec 28, 2001 |
|
|
|
10162460 |
|
|
|
|
60346078 |
Oct 26, 2001 |
|
|
|
Current U.S.
Class: |
128/200.23 |
Current CPC
Class: |
A61K 9/0078 20130101;
A61K 31/137 20130101; A61K 31/4745 20130101; A61K 31/137 20130101;
A61K 31/46 20130101; A61K 31/46 20130101; A61K 31/44 20130101; A61K
2300/00 20130101; A61K 2300/00 20130101 |
Class at
Publication: |
128/200.23 |
International
Class: |
A61M 11/00 20060101
A61M011/00 |
Claims
1. A system for inducing bronchodilation or providing relief of
bronchospasm in an individual suffering from chronic obstructive
pulmonary disease, said system comprising: (a) one or more single
dispensing containers; and (b) an aqueous inhalation solution
comprising a therapeutically effective amount of albuterol and a
therapeutically effective amount of about 0.001 mg to about 1.0 mg
of ipratropium bromide; wherein the aqueous inhalation solution is
prefilled in each of the one or more dispensing containers as a
premixed, premeasured, single unit dose of about 0.1 ml to about
0.5 ml, the aqueous inhalation solution administered to the
individual from a nebulizer chamber such that the mist is removed
from the nebulizer chamber in less than 12 minutes when said
aqueous inhalation solution is introduced into a high performance
nebulizer.
2. The system of claim 1, wherein each of the one or more
containers is prefilled with about 0.5 ml of the inhalation
solution.
3. The system of claim 1, wherein said amount of albuterol ranges
from about 2.0 mg to about 3.0 mg.
4. The system of claim 1, wherein the albuterol is albuterol base,
and said amount of albuterol base is about 2.5 mg and the amount of
ipratropium is about 0.5 mg.
5. The system of claim 1, wherein the inhalation solution in each
of the one or more containers is sterile.
6. The system of claim 1, wherein the inhalation solution in each
of the one or more containers is free of benzalkonium chloride.
7. The system of claim 1, wherein the system further comprises a
label which indicates that the inhalation solution can be used to
relieve bronchospasm associated with chronic obstructive pulmonary
disease.
8. The system of claim 7, wherein said label comprises instructions
for using the solution to relieve said bronchospasm.
9. The system of claim 7, wherein said label comprises prescribing
information comprising efficacy, dosage, administration,
contraindication and adverse reaction information pertaining to the
inhalation solution in the container.
10. The system of claim 1, wherein the mist is removed from the
nebulizer chamber in less than 10 minutes when said formulation is
introduced into a high performance nebulizer.
11. The system of claim 1, wherein the mist is removed from the
nebulizer chamber in less than 8 minutes when said formulation is
introduced into a high performance nebulizer.
12. The system of claim 1, wherein the mist is removed from the
nebulizer chamber in less than 6 minutes when said formulation is
introduced into a high performance nebulizer.
13. The system of claim 1, wherein the mist is removed from the
nebulizer chamber in less than 4 minutes when said formulation is
introduced into a high performance nebulizer.
14. A system for inducing bronchodilation or providing relief of
bronchospasm in an individual suffering from chronic obstructive
pulmonary disease, said system comprising: (a) one or more single
dispensing containers; and (b) an aqueous inhalation solution
comprising a therapeutically effective amount of albuterol and a
therapeutically effective amount of about 0.001 mg to about 1.0 mg
of ipratropium bromide; wherein the aqueous inhalation solution is
prefilled in each of the one or more dispensing containers as a
premixed, premeasured, single unit dose of about 0.1 ml to about
0.5 ml, the aqueous inhalation solution administered to the
individual from the one or more dispensing containers.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 11/037,574 filed Jan. 18, 2005, that is a continuation-in-part
of U.S. application Ser. No. 10/417,723, now abandoned, filed Apr.
15, 2003, and is also a continuation-in-part of International
Application PCT/US04/011705 filed Apr. 15, 2004. The latter two
applications are continuations-in-part of U.S. application Ser. No.
10/162,460, now U.S. Pat. No. 6,632,842, filed Jun. 3, 2002, which
is a continuation-in-part of U.S. application Ser. No. 10/034,657,
now abandoned, filed Dec. 28, 2001, and International Application
PCT/US02/33353 filed Oct. 18, 2002, which both claim priority under
35 U.S.C. .sctn.119 from U.S. Provisional Application Ser. No.
60/346,078 filed Oct. 26, 2001. The entire disclosure of each of
these prior applications is incorporated herein by reference in its
entirety. Both above-identified international applications were
published in English under PCT Article 2(2) under Publication Nos.
WO04/091536 and WO03/037159, respectively.
FIELD OF THE INVENTION
[0002] The present invention relates to a combination
bronchodilator therapy for relieving symptoms associated with
chronic obstructive pulmonary disease, and methods of using the
same. The present invention also relates to a method of making said
combination bronchodilator.
BACKGROUND OF INVENTION
[0003] Chronic obstructive pulmonary disease (COPD) is a slowly
progressive airway disease that produces a decline in lung function
that is not fully reversible. The airway limitation in COPD is
associated with an abnormal inflammatory response of the lungs to
noxious particles or gases.
[0004] In the U.S., an estimated 16 million Americans have been
diagnosed with some form of COPD, and as many as 16 million others
have the condition but have not yet been diagnosed. According to
the U.S. Centers for Disease Control and Prevention, COPD is the
fourth leading cause of death in the U.S. (behind heart disease,
cancer and stroke), claiming the lives of 112,000 Americans
annually.
[0005] In terms of health care utilization, the number of physician
visits for COPD in the U.S. increased from 9.3 million to 16
million between 1985 and 1995. The number of hospitalizations for
COPD in 1995 was estimated to be about 500,000. Although
prevalence, hospitalization and death rates for COPD are higher in
men than women, death rates have risen faster in women in recent
years. COPD is clearly a major and growing health care threat in
the U.S. and throughout the rest of the world.
[0006] In the prior art, antimicrobial agents such as benzalkonium
chloride (BAC) are often present in inhalation solutions used to
treat COPD. The presence of BAC in these solutions generally does
not affect the short-term (single dose) bronchodilator response.
However, case reports suggest that repeated use of COPD treatments
with BAC may result in paradoxic bronchoconstriction. When inhaled
by COPD subjects, BAC may also cause dose-dependent
bronchoconstriction. Despite these side effects, many commercially
available inhalation solutions contain BAC.
[0007] In addition, treatments for COPD often come in multiple
dosage units and must be diluted to specific concentrations
suitable for treating patients. This poses several problems. For
instance, COPD treatments requiring administration of a single dose
unit from multiple dosage units sometimes lack proper mixing or
diluting instructions, or the instructions for preparing and using
the COPD treatment may be hard to follow or can be easily lost. Of
even greater import is haphazard diluting or mixing of COPD
medications, which can result in administering the wrong dosage.
This could be especially harmful for patients less tolerant to
higher dosages of asthma medications. Incorrect mixing can also
result in treatment failure such that additional medical attention
is required, thereby increasing the time, expense and personnel
costs associated with therapy.
[0008] There is, therefore, a need for an improved inhalation
solution, system, kit and method for relieving symptoms associated
with COPD.
SUMMARY OF THE INVENTION
[0009] One object of the present invention is to provide a dual
bronchodilator inhalation solution to relieve bronchospasm in
patients suffering from COPD.
[0010] Another object of the present invention is to provide a
prepackaged, sterile, premixed, premeasured albuterol and
ipratropium inhalation solution for the relief of bronchospasm in
patients suffering from COPD.
[0011] It is yet another object of the present invention to provide
a BAC-free albuterol and ipratropium inhalation solution to treat
bronchospasm associated with COPD.
[0012] A further object of the present invention is to provide a
method of administering an albuterol and ipratropium inhalation
formulation for relief of bronchospasm associated with COPD.
[0013] An additional object of the present invention is to provide
a kit and/or system for administering a dual bronchodilator to
relieve bronchospasm associated with COPD.
[0014] A further object of the present invention is to provide a
process for making an albuterol and ipratropium inhalation solution
for use in relieving bronchospasm associated with COPD.
[0015] Another object of the invention includes a device for use in
relieving the symptoms of COPD.
[0016] Other objects, features and advantages of the present
invention will be apparent to those of ordinary skill in the art in
view of the following detailed description of the invention and
accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0017] FIGS. 1-4 depict a non-limiting example of administering the
inhalation solution of the present invention by a nebulizer.
[0018] FIG. 5 depicts a non-limiting example of a unified
prepackaged kit or system of the present invention.
[0019] FIG. 6 depicts a non-limiting example of one or more
pre-filled containers comprising the inhalation system of the
present invention.
[0020] FIG. 7 depicts a non-limiting example of a label utilized in
the present invention.
[0021] FIG. 8 is a graph illustrating the time course of FEV.sub.1
response after dosing with albuterol alone, ipatropium alone, and
the combination of albuterol and ipatropium according to the
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0022] Albuterol
[0023] The present invention relies on the bronchodilation effects
of albuterol to provide relief from symptoms associated with COPD.
As used herein, the term "albuterol" includes, but is not limited
to, any form of albuterol that is capable of producing a desired
bronchodilation effect in patients, including, but not limited to,
all tautomeric forms, enantomeric forms, stereoisomers, anhydrides,
acid addition salts, base salts, solvates, analogues and
derivatives of albuterol, or any mixture thereof.
[0024] In the present invention, acceptable salts of albuterol may
include, but are not limited to, hydrochloride, sulfate, maleate,
tartrate, citrate and the like. These salts are described in U.S.
Pat. No. 3,644,353, which is incorporated herein by reference in
its entirety.
[0025] In the present invention, the preferred salt of albuterol is
sulfate. In an alternative embodiment, the inhalation solution of
the present invention comprises the sulfate salt of racemic
albuterol, or it may comprise at least substantially of a single
isomer of albuterol. Albuterol sulfate is a relatively selective
beta-2-adrenergic bronchodilator with an empirical formula of
C.sub.13H.sub.21NO.sub.3. The chemical name for albuterol sulfate
is
.alpha..sup.1-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-.alpha.,.alpha-
.'-diol sulfate (2:1)(salt), and its established chemical structure
is as follows:
##STR00001##
[0026] Ipratropium
[0027] The present invention also relies on the bronchodilation
effect of ipratropium to provide relief from symptoms associated
with COPD. Ipratropium is an anticholinergic bronchodilator. As
used herein, the term "ipratropium" includes, but is not limited
to, any form of ipratropium which is capable of producing a desired
bronchodilation effect in patients suffering from COPD, including,
but not limited to, all tautomeric forms, enantomeric forms,
stereoisomers, anhydrides, acid addition salts, base salts,
salvates, analogues, derivatives of ipratropium, or any mixture
thereof.
[0028] In the present invention, acceptable salts of ipratropium
may include, but are not limited to, halide salts such as bromide,
chloride and iodide. These and other acceptable salts are described
in U.S. Pat. No. 3,505,337, which is incorporated herein by
reference in its entirety. In one alternative embodiment, the
inhalation solution of the present invention comprises racemic
ipratropium bromide, or it may comprise at least substantially of a
single isomer of ipratropium bromide.
[0029] In one embodiment of the present invention, the preferred
salt of ipratropium is bromide, which is chemically described as
8-azoniabicyclo [3.2.1]-octane, 3-(3,
hydroxyl-1-oxo-2-phenylpropoxy)-8methyl-8-(1-methylethyl)-bromide,
monohydrate, (endo, syn)-, (+)-. Ipratropium bromide has a
molecular weight of 430.4 and the empirical formula
C.sub.20H.sub.30BrNO.sub.3.H.sub.2O. It is freely soluble in water
and lower alcohol, and is insoluble in lipohilic solvents such as
ether, chloroform and fluorocarbon. The established chemical
structure of ipratropium bromide is as follows:
##STR00002##
[0030] In the present invention, the albuterol and ipratropium may
be provided in a variety of pharmaceutically acceptable vehicles,
including, but not limited to, water or any other aqueous solution
comprising a pharmaceutically acceptable amount of an osmotic
agent.
[0031] In one alternative embodiment, the inhalation solution of
the present invention comprises a therapeutically effective amount
of albuterol and ipratropium. As used herein, the phrase
"therapeutically effective amount of albuterol and/or ipratropium"
means a safe and tolerable amount of both compounds, as based on
industry and/or regulatory standards. Such amount being sufficient
to effectively induce bronchodilation and/or provide relief of
bronchospasm in patients suffering form COPD.
[0032] In the inhalation solution of the present invention, a
therapeutically effective amount of albuterol may include from
about 0.63 mg to about 4.2 mg albuterol. Here, the potency of the
albuterol is equivalent to from about 0.75 mg to about 5 mg of
albuterol sulfate. In an alternative embodiment, a therapeutically
effective amount of albuterol may include about 2.5 mg
albuterol.
[0033] In another alternative embodiment of the present invention,
a therapeutically effective amount of albuterol may include from
about 0.60 mg to about 5.0 mg albuterol, including the following
intermediate ranges of albuterol: about 0.60 mg to about 0.70 mg;
about 0.71 mg to about 0.80 mg; about 0.81 mg to about 0.90 mg;
about 0.91 mg to about 1.00 mg; about 1.01 mg to about 1.10 mg;
about 1.11 mg to about 1.20 mg; about 1.21 mg to about 1.30 mg;
about 1.31 mg to about 1.40 mg; about 1.41 mg to about 1.50 mg;
about 1.51 mg to about 1.60 mg; about 1.61 mg to about 1.70 mg;
about 1.71 mg to about 1.80 mg; about 1.81 mg to about 1.90 mg;
about 1.91 mg to about 2.00 mg; about 2.01 mg to about 2.10 mg;
about 2.11 mg to about 2.20 mg; about 2.21 mg to about 2.30 mg;
about 2.31 mg to about 2.40 mg; about 2.41 mg to about 2.50 mg;
about 2.51 mg to about 2.60 mg; about 2.61 mg to about 2.70 mg;
about 2.71 mg to about 2.80 mg; about 2.81 mg to about 2.90 mg;
about 2.91 mg to about 3.00; about 3.01 to about 3.10; about 3.11
to about 3.20; about 3.21 to about 3.30 mg; about 3.31 mg to about
3.40 mg; about 3.41 mg to about 3.50 mg; about 3.51 mg to about
3.60 mg; about 3.61 to about 3.70 mg; about 3.71 to about 3.80 mg;
about 3.81 mg to about 3.90 mg; about 3.91 mg to about 4.0 mg;
about 4.01 mg to about 4.10 mg; about 4.11 mg to about 4.20 mg;
about 4.21 mg to about 4.30 mg; about 4.31 mg to about 4.40 mg;
about 4.41 mg to about 4.50 mg; about 4.51 mg to about 4.60 mg;
about 4.61 mg to about 4.70 mg; about 4.71 mg to about 4.80 mg;
about 4.81 mg to about 4.90 mg; about 4.91 mg to about 5.00 mg.
[0034] In another alternative embodiment of the present invention,
a therapeutically effective amount of albuterol may include from
about 0.75 mg to about 5.0 mg albuterol sulfate, including the
following intermediate amounts: about 0.75 mg to about 0.80 mg;
about 0.81 to about 0.90 mg; about 0.91 mg to about 1.00 mg; about
1.01 mg to about 1.10 mg; about 1.11 mg to about 1.20 mg; about
1.21 mg to about 1.30 mg; about 1.31 mg to about 1.40 mg; about
1.41 mg to about 1.50 mg; about 1.51 mg to about 1.60 mg; about
1.61 mg to about 1.70 mg; about 1.71 mg to about 1.80 mg; about
1.81 mg to about 1.90 mg; about 1.91 mg to about 2.00 mg; about
2.01 mg to about 2.10 mg; about 2.11 mg to about 2.20 mg; about
2.21 mg to about 2.30 mg; about 2.31 mg to about 2.40 mg; about
2.41 mg to about 2.50 mg; about 2.51 mg to about 2.60 mg; about
2.61 mg to about 2.70 mg; about 2.71 mg to about 2.80 mg; about
2.81 mg to about 2.90 mg; about 2.91 mg to about 3.00; about 3.01
to about 3.10; about 3.11 to about 3.20; about 3.21 to about 3.30
mg; about 3.31 mg to about 3.40 mg; about 3.41 mg to about 3.50 mg;
about 3.51 mg to about 3.60 mg; about 3.61 to about 3.70 mg; about
3.71 to about 3.80 mg; about 3.81 mg to about 3.90 mg; about 3.91
mg to about 4.0 mg; about 4.01 mg to about 4.10 mg; about 4.11 mg
to about 4.20 mg; about 4.21 mg to about 4.30 mg; about 4.31 mg to
about 4.40 mg; about 4.41 mg to about 4.50 mg; about 4.51 mg to
about 4.60 mg; about 4.61 mg to about 4.70 mg; about 4.71 mg to
about 4.80 mg; about 4.81 mg to about 4.90 mg; about 4.91 mg to
about 5.00 mg.
[0035] In another alternative embodiment of the present invention,
a therapeutically effective amount of albuterol may include from
about 0.020% to about 0.14% by weight albuterol, including the
following intermediate ranges: about 0.020 wt % to about 0.029 wt
%; about 0.030 wt % to about 0.039 wt %; about 0.040 wt % to about
0.049 wt %; about 0.050 wt % to about 0.059 wt %; about 0.060 wt %
to about 0.069 wt %; about 0.070 wt % to about 0.079 wt %; about
0.080 wt % to about 0.089 wt %; about 0.090 wt % to about 0.099 wt
%; about 0.10 wt % to about 0.14 wt %.
[0036] In another alternative embodiment, a therapeutically
effective amount of albuterol may include from about 0.1% to about
5.0% by weight albuterol, including the following intermediate
ranges: about 0.2% to about 0.5%; about 0.5% to about 0.75%; about
0.75% to about 1.0%; 1.0% to about 1.25%; about 1.25% to about
1.50%; 1.50% to about 1.75%; 1.75% to about 2.0%; about 2.0% to
about 2.25%; about 2.25% to about 2.50%; 2.50% to about 2.75%; to
about 2.75% to about 3.0%; about 3.0% to about 3.5%; about 3.5% to
about 4.0%; 4.0% to about 4.5%; about 4.5% to about 5.0%. In
alternative embodiment, the present invention comprises 1.25%
albuterol base (equivalent to 1.5% albuterol sulfate.
[0037] In yet another alternative embodiment of the present
invention a therapeutically effective amount of albuterol may
include from about 0.025% to about 0.17% by weight albuterol
sulfate, including the following intermediate ranges: about 0.025
wt % to about 0.029 wt %; about 0.030 wt % to about 0.039 wt %;
about 0.040 wt % to about 0.049 wt %; about 0.050 wt % to about
0.059 wt %; about 0.060 wt % to about 0.069 wt %; about 0.070 wt %
to about 0.079 wt %; about 0.080 wt % to about 0.089 wt %; about
0.090 wt % to about 0.099 wt %; about 0.10 wt % to about 0.17 wt
%.
[0038] In another alternative embodiment of the present invention,
a therapeutically effective amount of ipratropium bromide may
include from about 0.01 mg to about 1.0 mg of ipratropium bromide.
Such therapeutically effective amount may also include the
following intermediate ranges of ipratropium bromide: about 0.01 mg
to about 0.02 mg; about 0.02 mg to about 0.04 mg; about 0.05 to
about 0.07 mg; about 0.08 mg to about 0.10 mg; about 0.11 mg to
about 0.13 mg; about 0.14 mg to about 0.16 mg; about 0.17 mg to
about 0.19 mg; about 0.20 mg to about 0.22 mg; 0.23 mg to about
0.25 mg; 0.26 mg to about 0.28 mg; about 0.29 mg to about 0.31 mg;
about 0.32 to about 0.34 mg; about 0.35 mg to about 0.37 mg; about
0.36 mg about 0.38 mg; about 0.39 mg to about 0.41 mg; about 0.42
mg to about 0.44 mg; about 0.45 mg to about 0.47 mg; about 0.48 mg
to about 0.50 mg; about 0.51 mg to about 0.53 mg; about 0.54 mg to
about 0.56 mg; about 0.57 mg to about 0.59 mg; about 0.60 mg to
about 0.62 mg; about 0.63 mg to about 0.65 mg; about 0.66 mg to
about 0.68 mg; about 0.69 mg to about 0.71 mg; about 0.72 mg to
about 0.74 mg; about 0.75 mg to about 0.77 mg; about 0.79 mg to
about 0.81 mg; about 0.82 mg to about 0.84 mg; about 0.85 mg to
about 0.87 mg; about 0.88 mg to about 0.91 mg; about 0.92 mg to
about 0.94 mg; about 0.95 mg to about 0.97 mg; about 0.98 mg to
about 1.00 mg.
[0039] In another alternative embodiment of the present invention,
a therapeutically effective amount of ipratropium may include from
about 0.001% to about 0.030% by weight ipratropium bromide,
including the following intermediate ranges of ipratropium bromide:
about 0.001 wt % to about 0.005 wt %; about 0.006 wt % to about
0.010 wt %; about 0.011 wt % to about 0.015 wt %; about 0.016 wt %
to about 0.020 wt %; about 0.021 wt % to about 0.025 wt %; 0.026 wt
% to about 0.030 wt %.
[0040] Most pharmaceutical inhalation solutions contain the
anti-microbial agent BAC. One problem with these solutions is that
the BAC may cause paradoxic bronchoconstriction if the solution is
administered repeatedly over short intervals. Another problem is
that, when inhaled by patients, the BAC can cause dose-dependent
bronchoconstriction. The inhalation solution of the present
invention may be provided without BAC, thereby making it suitable,
especially in an emergency situation, where the inhalation solution
is administered repeatedly over a short period of time. Also,
administering a BAC-free inhalation solution to a patient reduces
the concomitant liability of adverse effects associated with BAC.
It also reduces the toxicity and other side effects associated with
BAC.
[0041] The inhalation solution of the present invention may also be
provided in sterile, unit dose treatments, thus eliminating the
need to include BAC in the solution. Moreover, as shown in Table 1,
in its sterile form the formulation of the present invention (which
comprises a therapeutically effective amount of albuterol sulfate
and ipratropium bromide) provides a stable inhalation solution such
that the formulation can be stored (e.g., on a shelf) for long
periods of time.
TABLE-US-00001 TABLE 1 Stability Data 0.083 wt % Albuterol Sulfate
and 0.017 wt % Ipratropium Bromide Assay* Albuterol Ipratropium
Osmolality sulfate bromide pH (mOsm/kg) Time zero 98 98 3.3 283
25.degree. C./ 12 months 105 99 3.4 285 35% RH 24 months 102 101
3.5 282 40.degree. C./ 3 months 100 99 3.5 284 15% RH 6 months 103
102 3.4 283 *as percent of label claim (0.083 wt % albuterol
sulfate and 0.017 wt % ipratropium bromide)
[0042] As stated, the compositions provided herein are stable. For
example, the compositions provided herein are stored between about
15.degree. C. and about 30.degree. C., and remain stable for a
relatively long period of time. In one embodiment, the compositions
are stored at 25.degree. C.
[0043] In another embodiment, the stability of the compositions
provided herein may contain greater than 80%, 85%, 90% or 95% of
the initial amount of active ingredient, e.g., Albuterol and
Ipratropium at a given temperature for a long period of time. Thus,
for example, a composition that is stable for 30 days at 25.degree.
C. would have greater than 80%, 85%, 90% or 95% of the initial
amount of active ingredients present in the composition at 30 days
following storage at 25.degree. C.
[0044] In another embodiment, the compositions herein are stable
during long term storage, in that the compositions are suitable for
administration to a subject in need thereof when they have been
stored for a length of time (i.e., shelf-life) for a period greater
than 1, 2 or 3 years at 25.degree. C. In other embodiments herein,
using Arrhenius Kinetics, >80% or >85% or >90% or >95%
estimated bronchodilating agent remains after such storage, for
example.
[0045] Other indications of the stability of the present
compositions can be shown in terms of by-products or degradation
products present over time, as shown in Tables 2 and 3 below.
TABLE-US-00002 TABLE 2 Albuterol degradation Range at 6 to
products/related compounds 24 months at Range in drug as % of
albuterol 25.degree. C. substance 1 5-2-((1,1-Dimethylethyl)
ND-0.012% w/w amino-1-hydroxyethyl)-2- hydroxybenzaldehyde 2
Bis-(2-hydroxy0-5- 0.09-0.174% w/w (2-tertbutylamino-
1-hydroxyethyl) phenylmethyl ether 3 2-tert-butylamino- 0.01-0.12%
w/w 1-(4-hydroxy-3- methoxymethylphenyl)- ethanol 4
Tert-butylamino-3- ND-0.0002% w/w chloro-4-hydroxy-5-
hydroxymethyl- acetophenone 5 Tert-butylamino-4-hydroxy- ND-0.002%
w/w 5-hydroxymethyl- acetophenone 6 1-(4-hydroxy-3- 0.0009-0.036%
w/w methylphenyl)- 2-(tert-butylamino) ethanol 7
1-(5-chloro-4-hydroxy- ND 3-hydroxymethylphenyl)-
2-(tert-butylamino) ethanol 8 Unknown 1 ND-0.07% by peak area 9 Any
other unknown ND-0.025% by peak area 10 Total 0.18-0.23% ND = none
detected
TABLE-US-00003 TABLE 3 Ipratropium degradation Range at up
products/related compounds to 24 months Range in drug as % of
ipratropium bromide at 25.degree. C. substance 1 Tropic acid
ND-0.08% w/w 2 8S-ipratropium bromide ND-0.058% w/w 3
N-isopropyl-noratropine ND 4 Ipratropium alcohol ND-0.038% w/w 5
Any other unknown ND 6 Atropic acid ND 7 Total (excluding APO-
ND-0.2% ipratropium) ND = none detected
[0046] In one embodiment, the compositions herein are at least
substantially clear, based on color measurement tests set forth by
the America Public Health Association ("APHA"). In another
embodiment of the present invention, the APHA color results for
compositions herein at up to 24 months at 25.degree. C. ranged from
0 to 5 units (mostly 0 units), as based on APHA standards.
[0047] In one embodiment, the process of the present invention
provides compositions having an albuterol content of about 2.5 mg
to about 2.75 mg per vial. In another alternative embodiment, the
process of the present invention provides compositions having an
Ipratropium content of about 0.45-0.55 mg per vial. In yet another
alternative embodiment, the process of the present invention
provides an average fill volume of about 2.84 to about 3.30 ml into
each vial.
[0048] In another alternative embodiment, the compositions of the
present invention may contain minimal amounts of contaminants
including, but not limited to the following (where the term "NMT"
means "not more than"):
TABLE-US-00004 TABLE 4 1. Volatiles Acetone about NMT 0.2 mcg/ml or
less ethyl acetate about NMT 0.3 mcg/ml or less n-heptane NMT 0.1
mcg/ml or less n-propylacetate NMT 0.3 mcg/ml or less Toluene NMT
0.3 mcg/ml or less 2-butanone none detected (signal/nose NMT 3)
Unknowns 2. Leachables Irganox 129 none detect (NMT 0.02 mcg/ml)
Extractable 1 none detected (signal/noise NMT 3) Extractable 2 none
detected (signal/noise NMT 3) Unknowns none detected (signal/noise
NMT 3)
[0049] In another alternative embodiment, compositions of the
present invention may contain minimal amounts of particulate
matter, including, but not limited to the following: NMT about 1000
to 5000, preferably about 3800 particles/vial >2 .PHI.m; NMT
about 10 to 100, preferably about 80 particles/vial >10 .PHI.m;
or NMT about 1 to 5, preferably about 3 particles/vial >25
.PHI.m.
[0050] In another embodiment of the present invention, the
inhalation solution may have a pH of about 2.0 to about 8.0. In
another embodiment of the claimed invention, the solution may have
a pH of about 3.0 to about 4.0, preferably a pH of about 3.5. The
pH may be adjusted with 1N hydrochloric acid or 1N sulfuric acid.
The inhalation solution of the present invention may also contain
sodium citrate at a concentration of about 0.1 to 0.5% (w/w),
preferably about 0.2% (w/w/) to control pH or may further contain a
buffer. General and biological buffers in the pH range of about
2.0-8.0 include but are not limited to the following: acetate,
barbital, borate, Britton-Robinson, cacodylate, citrate, collidine,
formate, maleate, McIlvaine, phosphate, Prideaux-Ward, succinate,
citrate-phosphate-borate (Teorell-Stanhagen), veronal acetate, MES,
BIS-TRIS, ADA, ACES, PIPES, MOPSO, BIS-TRIS PROPANE, BES, MOPS,
TES, HEPES, DIPSO, MOBS, TAPSO, TRIZMA, HEPPSO, POPSO, TEA, EPPS,
TRICINE, GLY-GLY, BICINE, HEPBS, TAPS, and AMPD buffers.
[0051] In another embodiment of the present invention, the
osmolality of the inhalation solution may be adjusted from about
150 to about 550 mOsm/kg. In other embodiments of the present
invention, the osmolality of the solution may be from about 275 to
about 325 mOsm/kg. In yet another embodiment, the composition may
have an osmolality of about 290 mOsm/kg. Tonicity adjusting agents
include but are not limited to the following excipients: ammonium
carbonate, ammonium chloride, ammonium lactate, ammonium nitrate,
ammonium phosphate, ammonium sulfate, ascorbic acid, bismuth sodium
tartrate, boric acid, calcium chloride, calcium disodium edetate,
calcium gluconate, calcium lactate, citric acid, dextrose,
diethanolamine, dimethyl sulfoxide, edetate disodium, edetate
trisodium monohydrate, fluorescein sodium, fructose, galactose,
glycerin, lactic acid, lactose, magnesium chloride, magnesium
sulfate, manitol, polyethyne glycol, potassium acetate, potassium
chlorate, potassium chloride, potassium iodide, potassium nitrate,
potassium phosphate, potassium sulfate, propylene glycol, silver
nitrate, sodium acetate, sodium bicarbonate, sodium biphosphate,
sodium bisulfite, sodium borate, sodium bromide, sodium cacodylate,
sodium carbonate, sodium chloride, sodium citrate, sodium iodide,
sodium lactate, sodium metabisulfite, sodium nitrate, sodium
nitrite, sodium phosphate, sodium propionate, sodium succinate,
sodium sulfate, sodium sulfite, sodium tartrate, sodium
thiosulfate, sorbitol, sucrose, tartaric acid, triethanolamine,
urea, urethan, uridine, and zinc sulfate.
[0052] In one embodiment, the inhalation solution of the present
invention is sterile. A benefit of a sterile inhalation solution is
that it reduces the possibility of introducing contaminants into
the patient when administered, thereby reducing the chance of an
opportunistic infection in the patient.
[0053] Non-adherence to COPD medication therapy and medication
error are considerable problems. These problems can be
significantly reduced by providing COPD patients a prepackaged,
premixed, premeasured amount of albuterol and ipratropium.
Providing these compounds in this fashion makes COPD therapy simple
because it increases convenience and eliminates confusion in
preparing appropriate dosages. These advantages are especially
significant where treatments often come in multiple dosage units
and must be diluted to specific concentrations suitable for
treating patients. As discussed previously, this poses several
problems.
[0054] The present invention overcomes the aforementioned problems
by providing therapeutically effective amounts of both albuterol
and ipratropium in prepackaged, premixed, premeasured and/or unit
dose amounts. In one embodiment, the present invention comprises
one or more prefilled containers. The one or more containers each
comprising a single unit dose of an aqueous solution comprising a
therapeutically effective amount of albuterol and ipratropium for
the treatment of COPD. Providing the inhalation solution in such a
manner eliminates the need to dilute or mix COPD medications to
obtain proper dosages for treatment. Also, no special pharmacy
compounding is required, thereby reducing the chance of medication
errors. Further, there is a lower risk of cross-contamination, and
less waste of medication when providing an inhalation solution in a
premixed, ready to use form.
[0055] Other features of the present invention include improved
user compliance and quality of life as compared to conventional
treatments for COPD. While the level of compliance of any COPD
treatment depends in part on the motivation of the user and the
skill of the individual dispensing the treatment, compliance
nevertheless may be improved by controlling factors such as the
ease with which the treatment may be administered, as well as the
desirability of receiving the treatment.
[0056] The present invention provides a convenient, fast and
reliable treatment for COPD and clearly represents an improvement
over traditional COPD treatments. Also, the present invention is
designed to facilitate user compliance by providing one or more
dispensing containers comprising a premixed, premeasured inhalation
solution comprising a single unit dose of a therapeutically
effective amount of albuterol and ipratropium for the treatment of
COPD. Such containers may be utilized in a method of treating COPD
or the containers may be incorporated in a system and/or kit for
treating the same.
[0057] In one alternative embodiment, the present invention is a
sterile, premixed, premeasured, BAC-free inhalation solution
comprising a single unit dose of a therapeutically effective amount
of albuterol and ipratropium in a single container. Each unit dose
container comprises 3.0 mg/3 ml of albuterol sulfate (equivalent to
2.5 mg of albuterol) and 0.5 mg ipratropium bromide in a sterile,
aqueous solution. Sodium chloride may be added to make the solution
isotonic and hydrochloric acid may be added to adjust pH of the
solution to about 4.0. The inhalation solution of the present
invention may or may not include a chelating agent, such as
EDTA.
[0058] In another alternative embodiment, the inhalation solution
of the present invention may be supplied as a 3 ml, sterile,
BAC-free, nebulizer solution comprising from about 0.20 to about
0.5 mg ipratropium bromide and from about 0.75 mg/3 ml to about 3.0
mg/3 ml of albuterol sulfate. The nebulizer solution is contained
in a unit-dose, low-density polyethylene (LDPE) container. Each
unit-dose container may be disposed in a foil pouch, and each foil
pouch may contain 5 or more unit-dose containers. Each foil pouch
containing the unit dose container may be disposed in a shelf
carton.
[0059] The present invention provides an albuterol and ipratropium
inhalation solution for treating different stages of COPD,
including but not limited to, stages 0 to III. Some characteristics
associated with the different stages of COPD are shown in Table 2.
The information in this table is presented for illustrative
purposes only. It is not intended to limit the scope of the
invention.
TABLE-US-00005 TABLE 2 Stage Severity Description 0 At risk Normal
spirometry Chronic symptoms (cough, sputum production) I Mild
FEV.sub.1/FVC < 70% FEV.sub.1 > 80% predicted With or without
chronic symptoms II Moderate FEV.sub.1/FVC < 70% 30% .gtoreq.
FEV.sub.1 < 80% predicted (IIA: 50% .gtoreq. FEV.sub.1 < 80%)
(IIB: 30% .gtoreq. FEV.sub.1 < 50%) With or without chronic
symptoms III Severe FEV.sub.1/FVC < 70% FEV.sub.1 < 30%
predicted or less than 50% predicted with respiratory failure or
clinical signs of right heart failure.
[0060] In the present invention, a therapeutically effective amount
of albuterol and ipratropium is administered to induce
bronchodilation and/or provide relief of bronchospasm associated
with COPD. Such amount of albuterol and ipratropium may be
administered to a patient after the onset of bronchospasm to reduce
breathing difficulties resulting from COPD. In another embodiment,
the albuterol and ipratropium may be administered prophylactically,
that is, to prevent COPD progression.
[0061] The quantity of albuterol and ipratropium to be administered
will be determined on an individual basis, and will be based at
least in part on consideration of the patient's size, the severity
of the symptoms to be treated, and the results sought. The actual
dosage (quantity of albuterol and ipratropium administered at a
time) and the number of administrations per day will depend on the
mode of administration, such as inhaler, nebulizer or oral
administration. For example, about 2.5 mg of albuterol and about
0.5 mg of ipratropium bromide administered by nebulization 4 times
per day with up to 2 additional 3 ml doses allowed per day, if
needed, would be adequate to produce the desired bronchodilation
effect in most patients.
[0062] Further, the albuterol and ipratropium inhalation solution
of the present invention may be administered together with one or
more other drugs. For example, an antiasthmatic drug such as
theophylline or terbutaline, or an antihistamine or analgesic such
as aspirin, acetaminophen or ibuprofen, may be administered with or
in dose temporal proximity to administration of a therapeutically
effective amount of albuterol. The present invention and the one or
more drugs may be administered in one formulation or as two
separate entities. According to the present invention, a
therapeutically effective amount of albuterol and ipratropium,
alone or in combination with another drug(s), may be administered
to a individual periodically as necessary to reduce symptoms of
COPD.
[0063] In another alternative embodiment, the inhalation solution
of the present invention may be administered by nebulizer. Such
nebulizer including, but not limited to, a jet nebulizer,
ultrasonic nebulizer and breath actuated nebulizer. Preferably, the
nebulizer is a jet nebulizer connected to an air compressor with
adequate airflow. The nebulizer being equipped with a mouthpiece or
suitable face mask. Specifically, a PARI-LC-PLUS.TM. nebulizer
(with face mask or mouthpiece) connected to a PRONEB.TM. compressor
may be used to deliver the inhalation solution of the present
invention to a patient. In an embodiment, the inhalation solution
may be administered by nebulizers manufactured, designed or sold by
Omron, such as the OMRON MICRO AIR.TM. Ultrasonic Nebulizer. Other
nebulizers may also include those manufactured, designed, or sold
by Aerogen.
[0064] In an alternative embodiment, the system and/or kit of the
present invention comprises an inhalation solution comprising a
therapeutically effective amount of albuterol and ipratropium in a
prepackaged, premeasured, premixed and/or single unit dose form for
the treatment of COPD. The inhalation solution may be sterile
and/or BAC-free.
[0065] In another embodiment, the present invention provides a
system and/or kit for organizing and storing one or more prefilled
dispensing containers, each container comprising a premixed,
premeasured inhalation solution. The inhalation solution comprising
a single unit dose of a therapeutically effective amount of
albuterol and ipratropium. Such system and/or kit may provide such
containers in prepackaged form. The one or more containers may be
comprised of plastic including, but not limited to, a
semi-permeable plastic such as LDPE. The container may also
comprise a TWIST-FLEX.TM. top, such top comprising an easy-to-grip
tab-like handle such that the container may be opened, for example,
by twisting off the tab by hand. The Twist-Flex.TM. top is
advantageous in that it allows for easy dispensing of the solution,
prevents spillage and eliminates the need to open the container or
tearing by cutting or tearing off the top, or the like, thereby
reducing cross-contamination. In one alternative embodiment, the
design of the container substantially conforms to those designs
illustrated in U.S. Pat. Des. Nos. 317,715; 296,869; 289,609; or
275,732, which are incorporated herein by reference. One or more of
the semi-permeable single unit dose containers may be prepackaged
in aluminum foil pouch, such that the foil provides a protective
barrier against environmental contaminants and light. Such a
barrier improves the shelf-life and stability of the inhalation
solution.
[0066] In another alternative embodiment, the present invention
comprises a prepackaged inhalation system and/or kit suitable for
patients suffering from COPD. Such prepackaged system and/or kit
comprising: (a) one or more single unit dosages of a
therapeutically effective amount of albuterol and ipratropium; (b)
administration instructions for the use of said unit dose as a
treatment for COPD; and (c) a dispensing container prefilled with
the one or more unit doses of albuterol and ipratropium.
[0067] In another alternative embodiment, the prepackaged
inhalation system and/or kit of the present invention provides one
or more premixed, premeasured single unit dose vials comprising a
therapeutically effective amount of albuterol and ipratropium for
the treatment of bronchospasm associated with COPD, and
instructions for using the same.
[0068] In one alternative embodiment, the present invention is
directed to a system for reducing medication error and enhancing
therapeutic compliance of an individual suffering from chronic
obstructive pulmonary disease, the prepackaged therapeutic system
comprising:
[0069] one or more dispensing containers; the one or more
containers each prefilled with about 0.1 ml to about 2.0 ml or 3 ml
of a sterile, benzlakonium chloride-free, premixed, premeasured
aqueous inhalation solution comprising a unit dose of a
therapeutically effective amount of albuterol and ipratropium
bromide; wherein the dosage of albuterol is about 2.5 mg and the
dosage of ipratropium bromide is about 0.5 mg; the inhalation
solution in each of the one or more containers is suitable for
nebulization in a nebulizer; the inhalation solution in each of the
one or more containers has a long shelf life;
[0070] one or more labels with indicia thereon, the indicia
comprising efficacy dosage, administration, contraindication and
adverse reaction data pertaining to the inhalation solution in each
of the one or more containers;
[0071] wherein the contraindication data comprises data indicating
that the inhalation solution in each of the one or more containers
is contraindicated for humans with hypersensitivity to atropine and
derivatives thereof; and
[0072] wherein the adverse reaction data comprises data indicating
that precipitation or worsening of narrow-angle glaucoma, acute eye
pain, blurred vision, paradoxical bronchospasm, wheezing,
exacerbation of chronic obstructive pulmonary disease symptoms,
drowsiness, aching, flushing, upper respiratory tract infection,
palpitations, taste perversion, elevated heart rate, sinusitis,
back pain and sore throat may occur after administrating the
inhalation solution in the one or more containers.
[0073] The dosage and administration data may comprise data
indicating that the recommended dose of the inhalation solution in
each of the one or more containers is about 2.5 mg of albuterol and
about 0.5 mg impratropium bromide in 3 ml of an aqueous solution
administered 4 times per day by nebulization with up to 2
additional recommended doses allowed per day, if needed. Also, the
adverse reaction data may comprise data indicating that immediate
hypersensitivity reactions to the inhalation solution in each of
the one or more containers may occur after administration of the
inhalation solution, said hypersensitivity reactions comprising
urticaris, angioedema, rash, pruritis, oropharyngeal, edema,
bronchospasm, and anaphylaxis. The adverse reaction data may also
comprise data indicating that allergic-type reactions may occur
after administrating the inhalation solution in the one or more
containers, including skin rash, prurities, and urticaria. The
adverse reaction data may further comprise data indicating a list
of one or more adverse events that may occur after administrating
the inhalation solution, said adverse events including chest pain,
diarrhea, dyspepsia, nausea, leg cramps, bronchitis, lung disease,
pharyngitis, pneumonia, and urinary tract infection.
[0074] In another alternative embodiment, the present prepackaged
therapeutic system and/or kit for treating bronchospasm in a
patient suffering from chronic obstructive pulmonary disease may
comprise.
[0075] one or more dispensing containers; the one more containers
each prefilled with 3 ml of a sterile, stable, premixed,
premeasured aqueous inhalation solution free of benzalkonium
chloride; the inhalation solution consisting of sodium chloride,
water, edetate disodium, an acid to adjust the pH of the inhalation
solution to about 4, and a unit dose of a therapeutically effective
amount of albuterol and ipratropium bromide, wherein the amount of
albuterol is about 2.50 mg and the amount of ipratropium bromide is
about 0.5 mg; the inhalation solution in each of the one or more
containers is suitable for nebulization in a nebulizer; said
inhalation solution having a long shelf life;
[0076] one or more labels with indicia thereon; the indicia
comprising efficacy, dosage, administration, contraindication and
adverse reaction information pertaining to the inhalation solution
in each of the one or more containers;
[0077] wherein the dosage and administration data comprises data
indicating that the recommended dose of the inhalation solution in
each of the one or more containers is about 2.5 mg of albuterol and
about 0.5 mg impratropium bromide in 3 ml of an aqueous solution
administered 4 times per day by nebulization with up to 2
additional recommended doses allowed per day, if needed;
[0078] wherein the contraindication data comprises data indicating
that the inhalation solution in each of the one or more containers
is contraindicated for humans with hypersensitivity to atropine and
derivatives thereof;
[0079] wherein the adverse reaction data comprises data indicating
that immediate hypersensitivity reactions to the inhalation
solution in each of the one or more containers may occur after
administrating the inhalation solution, said hypersensitivity
reaction including urticaris, angioedema, rash, pruritis,
oropharyngeal, edema, bronchospasm, and anaphylaxis;
[0080] wherein the adverse reaction data comprises data indicating
that allergic-type reactions may occur after administrating the
inhalation solution in the one or more containers; said allergic
type reaction, including skin rash, prurities, and urticaria;
[0081] wherein the adverse reaction data comprises data indicating
that precipitation or worsening of narrow-angle glaucoma, acute eye
pain, blurred vision, paradoxical bronchospasm, wheezing,
exacerbation of chronic obstructive pulmonary disease symptoms,
drowsiness, aching, flushing, upper respiratory tract infection,
palpitations, taste perversion, elevated heart rate, sinusitis,
back pain and sore throat may occur after administrating the
inhalation solution in the one or more containers; and
[0082] the adverse reaction data includes a list of one or more
adverse events that may occur after administration of the
inhalation solution in each of the one or more containers; the
adverse events including chest pain, diarrhea, dyspepsia, nausea,
leg cramps, bronchitis, lung disease, pharyngitis, pneumonia, and
urinary tract infection.
[0083] The prepackaged inhalation system and/or kit may be provided
in one of any number of forms, including, but not limited to, a box
containing one or more prepackaged, unit dose vials or a box
containing individual packages or pouches comprising one or more
unit dose vials. For example, an embodiment of a unified
prepackaged system and/or kit for treating COPD in patients is
depicted in FIG. 5. Specifically, FIG. 5 depicts support package
(10). Support package (10) may include, but is not limited to, a
box, carton or any other enclosed container. The support package
comprising one or more prepackaged, pre-filled dispensing
containers (21-25). Each container comprising a premixed,
premeasured inhalation solution. The inhalation solution comprising
a unit dose of a therapeutically effective amount of albuterol and
ipratropium for treating COPD. The inhalation solution may be
provided in sterile and/or BAC-free form.
[0084] Support package (10) may also incorporate one or more labels
(13) therein. One or more labels (13) may comprise indicia (14)
indicating that the inhalation solution can be used to relieve
symptoms associated with COPD, such as bronchospasm. The label may
also comprise indicia (15) which provides instructions for using
the inhalation solution to relieve such symptoms. As used herein
"indicia" includes, but is not limited to, wording, pictures,
drawings, symbols and/or shapes. A non-limiting example of the
indicia that may appear on the one or more labels (13) is shown in
FIG. 7. The one or more labels may be positioned on one or more
surfaces of support package (10) or a separate sheet, or any
combination thereof. Support package (10) may also incorporate lid
(16) to enclose the packaging material therein.
[0085] The system and/or kit of the present invention may also
include a label and/or instructions designed to facilitate user
compliance. For example, in an embodiment, a system and/or kit of
the present invention comprises packaging material containing one
or more prepackaged vials comprising a sterile, premixed,
premeasured unit dose of an inhalation solution comprising a
therapeutic effective amount of albuterol and ipratropium. The
packaging material may further comprise a label indicating that
each vial can be used with a nebulizer for the relief of symptoms
associated with COPD, such as bronchospasm. Such instructions may
also include instructions on dosage for each nebulizer treatment,
as well as instructions for administration, such as by nebulizer.
The instructions may be positioned on one or more surfaces of the
packaging material therein, or the instructions may be provided on
a separate sheet, or any combination thereof.
[0086] The present invention is also directed to a method of
treating symptoms associated with COPD, including bronchospasm,
wherein a therapeutically effective amount of albuterol and
ipratropium may be administered as a unit dose. Such unit dose may
be in the form of a nebulizer solution.
[0087] In another embodiment, the present invention is directed to
a method for inducing bronchodilation or providing relief of
bronchospasm in a patient suffering from chronic obstructive
pulmonary disease, said method comprising the step of:
[0088] providing the patient a prepackaged therapeutic system
comprising:
[0089] one or more dispensing containers; the one or more
containers each prefilled with about 3 ml of a sterile,
benzalkonium chloride-free, premixed, premeasured aqueous
inhalation solution comprising a unit dose of a therapeutically
effective amount of albuterol and ipratropium bromide; wherein the
amount of albuterol is about 2.5 mg and the amount of ipratropium
bromide is about 0.5 mg; the inhalation solution in each of the one
or more containers is suitable for nebulization in a nebulizer; the
inhalation solution in each of the one or more containers has a
long shelf life;
[0090] providing the patient or prescriber of the prepackaged
therapeutic system dosage, administration, contraindication and
adverse reaction data pertaining to the inhalation solution in each
of the one or more containers;
[0091] wherein the contraindication data comprises data indicating
that the inhalation solution in each of the one or more containers
is contraindicated for humans with hypersensitivity to atropine and
derivatives thereof; and
[0092] wherein the adverse reaction data comprises data indicating
that precipitation or worsening of narrow-angle glaucoma, acute eye
pain, blurred vision, paradoxical bronchospasm, wheezing,
exacerbation of chronic obstructive pulmonary disease symptoms,
drowsiness, aching, flushing, upper respiratory tract infection,
palpitations, taste perversion, elevated heart rate, sinusitis,
back pain and sore throat may occur after administrating the
inhalation solution in the one or more containers.
[0093] In the present method, the dosage and administration data
may inform the patient or prescriber the recommended dose of the
inhalation solution in each of the one or more containers is about
2.5 mg of albuterol and 0.5 mg impratropium bromide in 3 ml of an
aqueous solution administered 4 times per day by nebulization with
up to 2 additional recommended doses allowed per day, if needed.
The adverse reaction may also inform the patient or prescriber that
immediate hypersensitivity reactions to the inhalation solution in
each of the one or more containers may occur after administration
of the inhalation solution, said hypersensitivity reactions
including urticaris, angioedema, rash, pruritis, oropharyngeal,
edema, bronchospasm, and anaphylaxis. The adverse reaction data may
further inform the patient or prescriber that allergic-type
reactions may occur after administrating the inhalation solution in
the one or more containers, including skin rash, prurities, and
urticaria. Also, the adverse reaction data may include a preprinted
list of one or more adverse events that may occur after
administrating the inhalation solution, said adverse events
comprising chest pain, diarrhea, dyspepsia, nausea, leg cramps,
bronchitis, lung disease, pharyngitis, pneumonia, and urinary tract
infection.
[0094] In another alternative embodiment, the present invention is
directed to a method for inducing bronchodilation or providing
relief of bronchospasm in a patient suffering from chronic
obstructive pulmonary disease, said method comprising the step
of:
[0095] providing a patient the prepackaged therapeutic system
comprising:
[0096] one or more dispensing containers; the one more containers
each prefilled with about 3 ml of a sterile, stable, premixed,
premeasured aqueous inhalation solution free of benzalkonium
chloride; the inhalation solution consisting of water, edetate
disodium, sodium chloride, and an acid to adjust the pH of the
inhalation solution to about 4, and a unit dose of a
therapeutically effective amount of albuterol and ipratropium
bromide, wherein the amount of albuterol is about 2.50 mg/3 ml and
the amount of ipratropium bromide is about 0.5 mg/3 ml; the
inhalation solution in each of the one or more containers is
suitable for nebulization in a nebulizer;
[0097] providing the patient or prescriber the prepackaged
therapeutic system efficacy, dosage, administration,
contraindication and adverse reaction data pertaining to the
inhalation solution in each of the one or more containers;
[0098] wherein the dosage and administration data informs the
patient or prescriber that the recommended dose of the inhalation
solution in each of the one or more containers is about 2.5 mg of
albuterol and 0.5 mg impratropium bromide in 3 ml of an aqueous
solution administered 4 times per day by nebulization with up to 2
additional recommended doses allowed per day, if needed;
[0099] wherein the contraindication data comprises information
indicating that the inhalation solution in each of the one or more
containers is contraindicated for humans with hypersensitivity to
atropine and derivatives thereof;
[0100] wherein the adverse reaction data informs the patient or
prescriber that immediate hypersensitivity reactions to the
inhalation solution in each of the one or more containers may occur
after administrating the inhalation solution in the one or more
containers, said hypersensitivity reaction including urticaris,
angioedema, rash, pruritis, oropharyngeal, edema, bronchospasm, and
anaphylaxis;
[0101] wherein the adverse reaction data informs the patient or
prescriber that possible allergic-type reactions may occur after
administering the inhalation solution in the one or more
containers, including skin rash, prurities, and urticaria;
[0102] wherein the adverse reaction data informs the patient or
prescriber that precipitation or worsening of narrow-angle
glaucoma, acute eye pain, blurred vision, paradoxical bronchospasm,
wheezing, exacerbation of chronic obstructive pulmonary disease
symptoms, drowsiness, aching, flushing, upper respiratory tract
infection, palpitations, taste perversion, elevated heart rate,
sinusitis, back pain and sore throat may occur after administrating
the inhalation solution in the one or more containers; and
[0103] the adverse reaction data includes a preprinted list of one
or more adverse events that may occur after administration of the
inhalation solution in each of the one or more containers; the
adverse events comprising chest pain, diarrhea, dyspepsia, nausea,
leg cramps, bronchitis, lung disease, pharyngitis, pneumonia, and
urinary tract infection.
[0104] In an alternative embodiment, the method of the present
invention comprises the step of administering to a patient a
therapeutically effective amount of albuterol and ipratropium. Such
solution may also be prepackaged, premixed, premeasured, BAC-free
and/or sterile. Such solution may also be in a single unit dose
vial.
[0105] In another alternative embodiment, the method of the present
invention comprises the step of administering to a patient in need
an inhalation solution comprising a therapeutically effective
amount of albuterol and ipratropium. The inhalation solution being
administered by nebulizer, more preferably a jet nebulizer
connected to an air compressor with adequate air flow.
[0106] In yet another alternative embodiment, in reference to FIGS.
1-4, the method of the present invention comprises the steps: (i)
placing an inhalation solution comprising a therapeutically
effective amount of albuterol and ipratropium (1) into a nebulizer
cup (2). The nebulizer may be powered by attachment to compressed
gas cylinders or an electrically driven compressor; (ii) using a
"T" adapter (3) to fit the nebulizer cup lid (4) to a mouthpiece
(5) or facemask (6); (iii) drawing the inhalation solution (1) up
by the velocity of a gas jet and fragmenting it into an aerosol;
(iv) passing the aerosol through the mouthpiece (5) or facemask (6)
to the patient (7) afflicted with bronchospasm; and (v) the patient
continues breathing until no more mist is formed in the nebulizer
chamber (8). This may occur in about 5-15 minutes.
[0107] In one alternative embodiment, the usual starting dosage for
patients may be about 2.50 mg albuterol and 0.5 mg ipratropium
administered 3 or 4 times daily, as needed by nebulization. To
administer these amounts of albuterol and ipratropium, the entire
contents of one unit dose vial (e.g., about 3.0 mg/3 ml albuterol
sulfate and 0.5 mg/3 ml ipratropium bromide) may be used.
Preferably, the nebulizer flow rate is adjusted to deliver the
albuterol and ipratropium over 5 to 15 minutes.
[0108] Further, in an alternative embodiment, the method of the
present invention comprises the steps: (i) preparing an inhalation
solution comprising a therapeutically effective amount of albuterol
and ipratropium by diluting one or more solutions comprising the
ipratropium or albuterol; and (ii) administering the inhalation
solution to a patient in need thereof.
[0109] The present invention also provides a process for making a
prepackaged, sterile, premixed, premeasured, and/or BAC-free
inhalation solution comprising a single unit dose of a
therapeutically effective amount of albuterol and ipratropium. In
such an embodiment, the method of the present invention comprises
one or more of the following steps: (i) adding at least a
therapeutically effective amount of albuterol and ipratropium in a
carrier, such as water; (ii) sterilizing the solution and sealing
the container. An osmotic adjusting agent may be added to adjust
the isotonicity of the solution. Preferably, the solution of the
present invention is isotonic, and an osmotic adjusting agent may
be added to adjust the isotonicity of the solution to about 280 to
about 320 mOsm/kg. Additionally, an acid (e.g., hydrochloride) may
be added to adjust the pH of the solution to a level of about 3.0
to about 5.0, preferably about 4.0.
[0110] In another embodiment, a process for making an inhalation
solution of the present invention comprises one or more of the
following steps: (i) adding at least a therapeutically effective
amount of albuterol and ipratropium in a carrier such as water;
(ii) placing the mixture in a container, and sterilizing the
mixture by steam sterilization, or any other sterilizing means
known in the art. Each albuterol and ipratropium mixture being
filled into a vial, and then packaged, stored and/or used directly.
Here, the resulting mixture is stable, and after sterilization, it
can be dispersed, if necessary, into multiple mixtures each
containing a unit dose of a therapeutically effective amount of
albuterol and ipratropium.
[0111] Osmotic adjusting agents that may be used include, but are
not limited to, sodium chloride, potassium chloride, zinc chloride,
calcium chloride and mixtures thereof. Other osmotic adjusting
agents may also include, but are not limited to, mannitol,
glycerol, and dextrose and mixtures thereof. In an alternative
embodiment, the present invention may comprise about 0.4 to about
1.0 weight percent ionic salt. Preferably, the present invention
comprises 0.9 wt % of an osmotic adjusting agent.
[0112] In an alternative embodiment, the inhalation solution of the
present invention may be prepared as follows: (i) fitting a
stainless steel formulation tank with a bottom drain and a
tri-blender for mixing; (ii) filling the tank with approximately
95% of the required amount of Purified Water USP at a temperature
of between 18.degree. C. to 25.degree. C.; while mixing, (iii)
adding EDTA USP, hydrochloric acid, and at least a therapeutically
effective amount of Albuterol Sulfate USP and Ipratropium Bromide
to the tank; (iv) continue mixing until all chemical components are
dissolved; (v) adding Purified Water USP to adjust the final
volume, if necessary, thus producing an albuterol and ipratropium
bromide mixture.
[0113] From the formulation tank, the albuterol and ipratropium
mixture may be pumped through sanitary delivery lines directly into
a form-fill-seal (FFS) machine. The albuterol and ipratropium
mixture may pass through a 0.2 micron sterilizing cartridge filter,
then into a reservoir tank, through a second 0.2 micron sterilizing
cartridge filter to the filling nozzles within the sterile air
shower compartment, and subsequently into formed vials of low
density polyethylene (LDPE). The albuterol and ipratropium mixture
may be sterile filled into the vials such that each vial contains a
single unit dose of a therapeutically effective amount of
albuterol. The filled vials may then be sealed. The FFS machine may
form, fill and seal the vials in a continuous operation under
aseptic conditions, thus producing a sterile product. For example,
cards of five filled vials (FIG. 6) may be overwrapped into a
protective laminated foil pouch using an autowrapper machine. Six
to twelve such pouches may then be packaged in a shelf carton, thus
forming a prepackaged therapeutic system for treating COPD in
patients. An appropriate label and instructions may be added in the
shelf carton.
[0114] The present invention is also directed to a method of
forming a unit-dose nebulizer solution comprising the step of: (i)
preparing a mixture containing a therapeutically effective amount
of albuterol and ipratropium bromide in a pharmaceutically
acceptable carrier. Said mixture being suitable for nebulization in
a nebulizer.
[0115] Additionally, the present invention is directed to a method
of making a prepackaged, stable, premeasured, and/or premixed
aqueous nebulizer solution for reducing medication error and
enhancing therapeutic compliance of an individual suffering from
chronic obstructive pulmonary disease. In one embodiment, the
method may comprise the steps of adding water, albuterol sulfate
and ipratropium bromide into a container at a temperature between
about 2.degree. C. and about 70.degree. C., or about 2.degree. C.
and about 50.degree. C., or about 2.degree. C. and about 30.degree.
C., or about 2.degree. C. and about 25.degree. C., or about
5.degree. C. and about 25.degree. C., preferably about 18.degree.
C. and about 25.degree. C. to form a solution, wherein the final
concentration of the albuterol and ipratropium bromide in the
solution ranges from about 0.06 wt. % to about 0.1 wt. % albuterol
and about 0.03 wt. % to about 0.1 wt. % ipratropium. The present
method may also comprise the step of adjusting the pH of said
solution to about 3.0 to about 4.0, preferably 3.5. The method of
the present invention may further comprise the step of adding
hydrochloric acid to adjust the pH of the inhalation solution. The
method of the present invention may further comprise adding
sufficient osmotic adjusting agent to the solution so that the
isotonicity of the solution is from about 280 mOsm/kg to about 320
mOsm/kg. The present method may further require filling the
solution into one or more dispensing vials, each vial being filled
with about 0.1 ml to about 5 ml, or about 0.1 ml to about 2.25 ml,
or about 0.1 ml to about 3.0 ml, about 0.5 ml to about 3.0 ml, or
about 0.5 ml to about 2.0 ml, or about 0.1 ml to about 2 ml,
preferably about 0.5 ml to about 1 ml, about 2 ml, or about 3 ml of
the solution such that the solution in the each vial comprises a
unit dose of a therapeutically effective amount of albuterol and
ipratropium bromide. Also, in another alternative embodiment, the
stability of the solution in the one or more dispensing containers
is such that the solution is therapeutically effective following
storage for 12 months at 25.degree. C. The solution may be suitable
for nebulization in a nebulizer.
[0116] The method may further comprise the step of sterile sealing
the one or more vials after the solution is filled in the one or
more vials. The method may further comprise the step of filing the
nebulizer solution into the one or more low density polyethylene
dispensing vials, wherein the solution filled in the one or more
dispensing vials comprises about 0.4 wt. % to about 1.0 wt. % ionic
salt, and the solution filled in the one or more dispensing vials
comprises about 0.9% of an osmotic adjusting agent. The method
further comprising the step of adding albuterol and ipratropium
comprises adding sufficient albuterol and ipratropium so that the
concentration of albuterol is about 0.083 wt. % and the
concentration of ipratropium bromide is about 0.017 wt. % in the
solution.
[0117] Drugs administered by nebulization play a major role in the
treatment of COPD. It has been shown that some patients have
difficulty inhaling sufficient amounts of the prescribed medication
from a nebulizer and this may be a reason for treatment failure.
However, one of the drawbacks of nebulization therapy is the number
of times it must be performed each day, and the amount of time each
treatment takes. For example, an individual may be required to
receive 4 doses of inhalation solution per day by nebulization. In
some instances, each nebulizer treatment takes about 15 minutes, or
more to deliver a 2.5 ml fill volume of a bronchodilator, though
the amount of time may vary depending on the model of the nebulizer
used. Thus, in one day, an individual may be required to spend an
hour or more to receive the necessary dosage of albuterol and
ipratropium to induce bronchodilation or obtain relief of
bronchospasm associated with COPD, for example. The time
requirements for nebulization therapy can be burdensome, and cause
individuals to skip required dosages during the day. The impact of
not following the prescribed dosage regimen could compromise the
individual's condition.
[0118] In one alternative embodiment, the volume of the
albuterol/ipratropium inhalation solutions of the present invention
is about 0.1 ml to about 2.25 ml, or about 0.1 ml to about 2 ml, or
about 1 ml to about 2 ml, or about 1.5 ml to about 2 ml, preferably
about 1 ml, about 1.5 ml, about 2.0 ml, or about 2.25 ml. In
another alternative embodiment, the volume of the
albuterol/ipratropium inhalation solution of the present invention
is about 0.05 ml to about 1.0 ml; 0.1 ml to about 0.9 ml; 0.1 ml to
about 0.8 ml; 0.1 ml to about 0.7 ml; 0.1 ml to about 0.6 ml; 0.1
ml to about 0.5 ml; 0.1 ml to about 0.4 ml; 0.1 ml to about 0.3 ml;
0.1 ml to about 2.0 ml. In one preferred embodiment the fill volume
of the albuterol/ipratropium inhalation solution of the present
invention is from about 0.05 ml to about 0.4 ml, preferably from
about 0.1 ml to about 3.0 ml, more preferably about 0.25 ml. While
no clinical trials or other experiments were carried out on these
volumes, it is believed that such volumes would be more beneficial
over conventional nebulizer solutions (e.g. 2.5 ml or 3.0 ml fill
volume) because they will enable the individual to receive more
medication (e.g., albuterol and ipratropium) in less time during
each nebulization treatment. Also, it is believed that the fill
volumes of the present invention will minimize common handling
complications with nebulizer therapy, and it may extend the life of
the nebulizer.
[0119] In one alternative embodiment, the fill volumes of the
present invention may reduce the time of each nebulization
treatment by at least 20%, 30%, 40%, 50%, 60%, 70% or 80% or more
over conventional nebulizer treatments (e.g. 2.5 ml or 3 ml fill
volume). In another alternative embodiment, the fill volumes of the
present invention may reduce each nebulization treatment to about
or less than about 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 minutes,
or any range therebetween less over conventional nebulizer
treatments (e.g. 2.5 ml or 3.0 ml fill volume). Reducing the amount
of time to complete the treatment means individuals will be more
likely to comply with the prescribed dosing regimen and achieve
optimal benefit from the medication prescribed.
[0120] Another drawback of conventional nebulizer treatments is the
loss of medication during administration. Conventional nebulizer
solutions comprise about 2.5 ml fill volume of inhalation solution,
or more. For example, when nebulizing an inhalation solution
comprising 2.5 ml or more, about 0.7 ml of the solution remains in
the nebulizer system after treatment, though the amount may vary
depending on the model of the nebulizer used. In these instances,
the individual is not receiving the prescribed dosage or optimum
dosage of inhalation medication. For example, in one day, due to
the residual medication remaining in the nebulizer system after
each treatment, an individual fails to receive approximately 2.1
ml, or more of the prescribed daily amount of medication.
[0121] It is believed that the fill volumes of the
albuterol/ipratropium inhalation solutions of the present invention
will result in lesser amounts of solution remaining in the
nebulizer system after treatment, when compared to conventional
inhalation solutions (e.g. 2.5 ml or 3 ml fill volume). Less
solution remaining in the nebulizer system means more medication
(e.g., albuterol and ipratropium) administered to the individual
during each treatment. In one alternative embodiment, the amount of
solution remaining in the nebulizer system after each treatment may
be less than 0.50 ml, or less than 0.30 ml, or less than 0.20 ml or
less than 0.10 ml or less than 0.05 ml of the albuterol/ipratropium
inhalation solutions of the present invention, e.g. an inhalation
solution comprising 2.5 mg albuterol and 0.5 mg ipratropium
bromide.
[0122] Important factors to effective nebulizer treatment is deep
inspiration to ensure deep penetration of the medication into the
lungs, and steady breath-holding to ensure good retention of the
medication in the lungs. It is believed that administering a fill
volume less than 2.0 ml, preferably from about 0.1 ml to about 0.3
ml, more preferably about 0.25 ml of an inhalation solution into a
nebulizer, for example, will optimize the therapeutic effect of the
individual's deep inspiration efforts during treatment, and will
optimize the therapeutic effect of the individual's breath-holding
efforts as well. This is due to the shorter treatment time and
increased concentration of the albuterol and ipratropium in the
solution.
[0123] Accordingly, in one alternative embodiment, the present
invention is a method of facilitating patient care, reducing
medication error, reducing nebulizer treatment time, improving the
efficiency and efficacy of nebulizing therapy or enhancing
therapeutic compliance of an individual suffering from COPD. In one
alternative embodiment, such method may comprise the step of
placing about 0.1 ml to about 2.0 ml of the albuterol/ipratropium
inhalation solutions of the present invention into a chamber of a
nebulizer. The nebulizer having a mouthpiece or facemask associated
with the chamber of the nebulizer. The mouthpiece or facemask is
positioned in close proximity to the individual's mouth or face.
The inhalation solution may be passed in a mist form from the
nebulizer chamber through the mouthpiece or facemask to the
individual while the individual breathes into the mouthpiece or
facemask. The individual continues breathing into the mouthpiece or
facemask until the nebulization treatment is finished. This may
take about or less than about 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1
or 0.5 minutes, or any range therebetween. In another alternative
embodiment, the treatment may be finished in about 60, 50, 40, 30,
20, 10, 5 or 1 second, or any range therebetween. In an alternative
embodiment, the nebulization treatment is finished when at least
substantially all the mist is removed from the nebulizer chamber.
This may take about or less than about 12, 11, 10, 9, 8, 7, 6, 5,
4, 3, 2, 1 or 0.5 minutes, or any range therebetween. In an
alternative embodiment, it may take about 60, 50, 40, 30, 20, 10, 5
or 1 second, or any range therebetween.
[0124] In another alternative embodiment, the system of the present
invention comprises one or more dispensing containers prefilled
with about 0.1 ml to about 2.0 ml, or about 0.1 ml to about 1.0 ml;
0.1 ml to about 0.9 ml; 0.1 ml to about 0.8 ml; 0.1 ml to about 0.7
ml; 0.1 ml to about 0.6 ml; 0.1 ml to about 0.5 ml; 0.1 ml to about
0.4 ml; 0.1 ml to about 0.3 ml; 0.1 ml to about 2.0 ml; about 0.5
ml to about 2.0 ml, or about 0.1 ml to about 2.25 ml, or about 1.0
ml to about 2.0 ml, or about 2.0 ml to about 2.4 ml of a premixed,
premeasured, aqueous inhalation solution comprising a single unit
dose of a therapeutically effective amount of albuterol and
ipratropium bromide.
[0125] In one preferred embodiment, the present invention comprises
0.05 ml to about 0.4 ml, preferably from about 0.1 ml to about 0.3
ml, more preferably about 0.25 ml. The amount of albuterol may
range from about 0.60 mg to about 5.0 mg, preferably about 2.5 mg.
The amount of ipratropium bromide may range from about 0.01 mg to
about 1.0 mg, preferably about 0.5 mg. In another alternative
embodiment, the amount of albuterol may range from about 2.0 mg to
about 3.0 mg, preferably about 2.5 mg. The solution may be suitable
for nebulization in a nebulizer, and the solution may be stable, in
that the inhalation solution is therapeutically effective following
storage for 12 months at 25.degree. C., for example. Also, in
another embodiment, the inhalation solution in each of the one or
more containers comprise a preservative or any other suitable
anti-microbial agent, such as benzalkonium chloride, or may be
preservative free. In one alternative embodiment, the inhalation
solution may comprise 0.001% to about 2.0%, or 0.001% to about
0.5%, or about 0.01% to about 0.1% of a preservative, such as
benzalkonium chloride, for example. The inhalation solution may
further comprise sodium chloride, water, and an acid to adjust the
pH of the inhalation solution to about 4, preferably about 3.5.
[0126] The system may further comprise a label that indicates that
the inhalation solution can be used to relieve bronchospasm
associated with chronic obstructive pulmonary disease. In one
alternative embodiment, the label may comprise indicia comprising
efficacy, dosage, administration, contraindication and adverse
reaction data pertaining to the inhalation solution in each of the
one or more containers. The contraindication data may comprise data
indicating that the inhalation solution in each of the one or more
containers is contraindicated for humans with hypersensitivity to
any of the ingredients contained in the inhalation solution. Also,
the adverse reaction data may comprise data indicating that lung
disease, bronchitis, diarrhea or phargaryngitis may occur after
administration of the inhalation solution. The dosage and
administration data may also comprise data indicating that the
recommended dose of the inhalation solution in each of the one or
more containers may be administered 1, 2, 3, 4, 5, 6, 7 or 8 times
per day by nebulization.
[0127] The present invention is also directed to a method of
reducing medication error and enhancing therapeutic compliance of
an individual suffering from chronic obstructive pulmonary disease.
In one such embodiment, the method comprises the step of
administrating to the individual at least one or more dispensing
vials of the inhalation solution described herein, for example.
Dispensing vials may include, but are not limited to, any container
comprising glass, low density polyethylene, or any other material
capable of preventing the solution from leaking out of the
container. The vial may be enclosed by any conventional means,
including but not limited to, screw cap, heat seal, snap-on top,
flip-top, twist-off stopper, peel away top, and the like.
[0128] In accordance with the present invention, the
albuterol/ipratropium inhalation solution may be stored in or
dispensed from any dispensing vial made of suitable plastic
material. For example, the dispensing vial may be constructed of
any suitable elastomeric material, such as olefin-based materials,
including but not limited to, polyethylene, ethylene-propylene
copolymers, ethylene-vinyl acetate copolymers, ethylene-acrylic
ester copolymers, iononomers, and combinations thereof.
Furthermore, polymers having barrier properties, such as
polyvinylidene chloride and ethylene-vinyl alcohol copolymers, as
well as polymers such as polyvinyl chloride, polyester, polyamide
and polyurethanes may also be used.
[0129] In an alternative embodiment, the present invention also
comprises a device for use in the relief of symptoms associated
with COPD, including bronchospasm. Such device may take the form of
a label, written instructions or any other form incorporating
indicia thereon. The device may comprise indicia that indicates
that a patient suffering from symptoms associated with COPD can be
treated with at least one prepackaged, sterile, premixed,
premeasured and/or BAC-free inhalation solution comprising a unit
dose of a therapeutically effective amount of albuterol and
ipratropium in a single vial. The inhalation solution being
suitable for nebulization in a nebulizer. The device may also
comprise indicia that provides instructions for utilizing the
inhalation solution to treat said symptoms in patients.
EXAMPLES
[0130] To evaluate the efficacy and safety of the inhalation
solution of the present invention, a double-blind, randomized,
positive control trial was performed. The design, results and
conclusion of the study are described in detail below.
[0131] Patients
[0132] A total of 863 patients were initially randomized for
enrollment in the trial. To be eligible for enrollment, patients
had to meet the criteria described in Table 3.
TABLE-US-00006 TABLE 3 Inclusion/Exclusion Criteria Design Element
Description Inclusion Diagnosis with COPD with an FEV.sub.1 between
25% and 65% of Criteria the normal predicted value. Age >40
years. Regular use of one or more bronchodilators for a minimum of
3 months prior to enrollment. History of at least 10 pack-years of
smoking. Ability to refrain from the use of theophylline,
salmeterol and oral .beta..sub.2 agonists for the duration of the
trial (as judged by the investigator). Ability to safely complete a
6-minute walk. Willingness to provide informed consent. Exclusion
Diagnosis of anthracosis, silicosis, any parenchymal disease
Criteria not attributable to COPD, polycythemia, or pulmonale,
hypoxia, or a primary diagnosis attributable to allergic rhinitis,
atopy, or COPD. Clinically significant obstructive urinary disease,
narrow-angle glaucoma, unstable angina pectoris or myocardial
infarction in the past 6 months, known drug abuse within the last
12 months, or hospitalization for pulmonary exacerbation within the
past 2 months. Known hypersensitivity to any component of the study
medications. Investigational drug use within 30 days of first dose
of study medication. Pregnancy or breastfeeding.
Interventions
[0133] The doses of each individual agent and the ipratropium and
albuterol combination were as shown in Table 4 below. All study
medications were administered 4 times per day (ideally every 6
hours) by inhalation using a PARI LC PLUS.TM. nebulizer and PARI
PRONEB.TM. compressor. Concomitant use of bronchodilators was
restricted during the trial. Oral and inhaled steroic use was
permitted throughout the trial, provided that dosing remained
constant.
TABLE-US-00007 TABLE 4 Study Medication Albuterol (base)
Ipratropium bromide Albuterol alone 2.5 mg/3 ml Ipratropium alone
0.5 mg/3 ml Albuterol and 2.5 mg/3 ml 0.5 mg/3 ml Ipratropium
Combination
[0134] Efficacy Results
[0135] Of the 863 patients who were randomized and began treatment,
289 withdrew prematurely from the trial, including 28 patients who
did not meet the inclusion/exclusion criteria and were
inappropriately enrolled. A total of 663 patients received both the
inhalation solution of the present invention and at least one other
study medication and completed at least one post-dose measurement
of FEV.sub.1. These subjects contributed to the 647 evaluable
comparisons in each portion of the primary analysis, as the
majority of patients completed treatment on all three study
medications.
[0136] The primary efficacy variable was the change from pre-dose
to peak FEV.sub.1 measured within 3 hours after dosing during the
crossover phase of the trial. As can be seen in Table 5, the mean
increase in FEV.sub.1 was significantly higher for the albuterol
and ipratropium combination than for either agent used alone. The
improvement for the combination over albuterol alone was 23.6% and
over ipratropium alone was 37.2%. The time course of FEV.sub.1
response is shown in FIG. 8.
TABLE-US-00008 TABLE 5 Efficacy Results in Crossover Phase
Combination vs. Albuterol Combination vs. Ipratropium Combination
Albuterol Combination Ipratropium Parameter n mean mean p value n
mean mean p value Peak FEV.sub.1 (liters) 647 0.387 0.313 <0.001
647 0.387 0.282 <0.001
[0137] During the parallel phase of the trial, separate groups of
patients self-administered only one of the three study medications
during the final 6 weeks of the trial. Results for the parallel
phase yielded results essentially identical to the crossover phase.
The albuterol and ipratropium combination maintained the same
magnitude of superiority over each component medication alone that
was observed during the crossover phase in peak FEV.sub.1
response.
Safety/Tolerability
[0138] Adverse reactions concerning the albuterol and ipratropium
combination were evaluated from the clinical trials described
above. Treatment-emergent adverse events that were reported by 1%
or greater of patients are summarized by medication in Table 6. As
can be seen, there were no differences between the albuterol and
ipratropium combination and the individual medication in incidence
of patients with adverse events across body systems.
TABLE-US-00009 TABLE 6 Adverse Event Reports (ADVERSE EVENTS
OCCURRING IN .gtoreq.1% OF TREATMENT GROUP(S) AND WHERE THE
COMBINATION TREATMENT SHOWED THE HIGHEST PERCENTAGE) Albuterol and
Ipratropium Body System Albuterol Ipratropium Combination COSTART
Term n (%) n (%) n (%) NUMBER OF PATIENTS 761 754 765 N (%)
Patients with A 327 (43.0) 329 (43.6) 367 (48.0) BODY AS A WHOLE
Pain 8 (1.1) 4 (0.5) 10 (1.3) Pain chest 11 (1.4) 14 (1.9) 20 (2.6)
DIGESTIVE Diarrhea 5 (0.7) 9 (1.2) 14 (1.8) Dyspepsia 7 (0.9) 8
(1.1) 10 (1.3) Nausea 7 (0.9) 6 (0.8) 11 (1.4) MUSCULO-SKELETAL
Cramps leg 8 (1.1) 6 (0.8) 11 (1.4) RESPIRATORY Bronchitis 11 (1.4)
13 (1.7) 13 (1.7) Lung Disease 36 (4.7) 34 (4.5) 49 (6.4)
Pharyngitis 27 (3.5) 27 (3.6) 34 (4.4) Pneumonia 7 (0.9) 8 (1.1) 10
(1.3) UROGENITAL Infection urinary tract 3 (0.4) 9 (1.2) 12
(1.6)
[0139] Additional adverse reactions reported in more than 1% of
patients treated with the albuterol and ipratropium combination
included constipation and voice alterations.
Example 2
[0140] Example 2 is a prophetic example of a nebulizable inhalation
solution of the present invention having about 0.5 ml fill volume.
It is provided to illustrate, but not limit, the present invention.
It is believed that prophetic Example 2 would be suitable for
inducing bronchodialation or providing relief of bronchospasm in an
individual 2 to 12 years suffering from COPD. The inhalation
solution may be a sterile, premixed, premeasured single unit dose.
It may also comprise all other attributes, features and ingredients
of the various embodiments of the present invention, as described
herein. Prophetic Example 2 may be administered to an individual in
accordance with one or more of the modes of administration
described herein.
TABLE-US-00010 TABLE 9 Ingredient Composition (% w/w) Range (% w/w)
Albuterol sulfate About 0.30 or about 0.15 0.1 to 2.5 (expressed as
sulfate) (expressed as sulfate) Ipratropium (anydrous) 0.102 0.008
to 0.5 Bromide EDTA 0.01 0.001 to 0.2 Sodium Chloride 0.82 0 to 0.9
1N HCl 0.046 0 to 1.4 Purified water q.s. q.s.
[0141] The figures and attachments herein are presented for
illustrative proposes only. They are not intended to limit the
scope of the invention. Further, it should be understood that
various changes and modifications to the presently preferred
embodiment described herein will be apparent to those skilled in
the art. Such changes and modifications can be made without
departing from the spirit and scope of the present invention and
without diminishing its attendant advantages. It is therefore
intended that such changes and modifications be covered by the
appended claims.
[0142] Also, the invention may suitably comprise, consist of or
consist essentially of the elements described herein, and the
invention described herein suitably may be practiced in the absence
of any element that is not specifically disclosed herein.
* * * * *